L- Pharmaceutical formulation with improved stability comprising Dapagliflozin L-proline

摘要

The present invention relates to a pharmaceutical formulation comprising dapagliflozin L-proline. Specifically, in the pharmaceutical formulation containing dapagliflozin L-proline, the low hygroscopicity of dapagliflozin L-proline does not contain a fluidizing agent and is manufactured by a dry granulation process, thereby providing excellent stability and content It relates to a pharmaceutical formulation having uniformity.